Biomx Inc - Asset Resilience Ratio
Biomx Inc (PHGE) has an Asset Resilience Ratio of 1.86% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHGE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Biomx Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PHGE total asset value.
Liquid Assets Composition Over Time
This chart breaks down Biomx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Biomx Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.11 Million | 1.86% |
| Total Liquid Assets | $1.11 Million | 1.86% |
Asset Resilience Insights
- Limited Liquidity: Biomx Inc maintains only 1.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biomx Inc Industry Peers by Asset Resilience Ratio
Compare Biomx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Biomx Inc (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Biomx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $25.03 Million | -- |
| 2022-12-31 | 4.39% | $2.00 Million | $45.53 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $77.99 Million | -- |
| 2020-12-31 | 28.21% | $19.85 Million | $70.36 Million | +17.35pp |
| 2019-12-31 | 10.86% | $10.00 Million | $92.12 Million | -57.65pp |
| 2018-12-31 | 68.51% | $31.05 Million | $45.33 Million | +60.26pp |
| 2017-12-31 | 8.25% | $1.15 Million | $13.99 Million | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more